• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

New Report Assesses Key Trends in the Political and Reimbursement Environment for Cancer Drugs

Posted on: Thursday, 10 April 2008, 15:01 CDT

Research and Markets (http://www.researchandmarkets.com/reports/c88172) has announced the addition of new Decision Resources report: Key Trends in the Political and Reimbursement Environment for Cancer Drugs to their offering.

Cancer therapies make up one of the fastest-growing therapeutic areas in the global pharmaceutical market. IMS Health expects global sales of cancer therapies to more than double in just four years, exceeding $65 billion in 2010. Not surprisingly, the pharmaceutical industry is eager to tap the potential of this market. A critical factor in this growth, in both the United States and the European market, is the ever-evolving reimbursement environment -- and the political trends that influence it.

Get the Answers You Need to Shape Your Strategy

Oncology drugs form one of the largest therapeutic areas of the global pharmaceutical market, with worldwide sales of almost $30 billion in 2006. What factors account for the success of this fast growing market? How is the pharmaceutical industry responding to this growth?

Increasingly restrictive reimbursement policies will continue to impose strict cost controls on cancer therapies. How will the U.S. Medicare system manage its funding policies? What changes are in store for cancer therapy reimbursements by commercial insurers? How will the new funding program in France affect its high rate of spending on cancer drugs? How will reform measures in Germany affect its reference pricing system. What changes are included in Italy's new national health system? Will the U.K.'s new Cancer Reform Strategy affect spending on cancer drugs?

The global market for oncology drugs will continue to grow vigorously in the coming years. Are the industry's pricing strategies expected to change in the worldwide market? What strategies will pharmaceutical companies undertake to expedite the launch of new drugs in Europe?

Scope

The fight against cancer is one of the highest healthcare priorities in all advanced economies: government funding systems; worldwide public and private reimbursement programs; payment policies for innovative cancer therapies.

U.S. and European government insurance systems are all under pressure to rein in healthcare costs: reimbursement for cancer therapies is a target for cost cutting; office-based cancer treatments create payment challenges for physicians; pharmaceutical companies need to establish an infrastructure for conducting price negotiations with payers.

Health technology assessment (HTA) now influences a wide span of product life cycles: earlystage R&D affected by the demands of HTA; evidence of clinical effectiveness needed to defend a drug against the threat of price cuts.

Illustrated figures: Percentages of private and Medicare plans that place restrictions on the use of select targeted cancer therapies.

Companies

Allgemeine Ortskrankenkasse Baden-Württemberg

Amgen

Biogen Idec

Bristol-Myers Squibb

DAK

Genentech

GlaxoSmithKline

ImClone Systems

IMS Health

Janssen-Cilag

Novartis

Oncology Metrics

OSI Pharmaceuticals

Pfizer

Roche

For more information visit http://www.researchandmarkets.com/reports/c88172.

Source: Business Wire

More News in this Category